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Abstract 1
Subacute neuroregression in association with raised neopterin and overexpression of interferon 2 stimulated genes (ISGs) could indicate a type 1 interferonopathy. Here we describe a novel 3 immunotherapy-responsive, clinico-immunological and imaging phenotype with evidence of innate 4 immune activation. Three children (patient 1: 22-month-old boy; patient 2: 5-year-old girl; patient 3: 4-5 year-old girl) presented with asymmetric bilateral mixed dystonia and spasticity, regression in language 6
(expressive more than receptive) and bulbar symptoms with no evidence of seizures. Symptoms 7 evolved over several weeks to months. Brain MRI changes mimicked cerebral atrophy, initially 8 asymmetric. CSF revealed raised neopterins. Blood RNA assay showed abnormal overexpression of 9
ISGs and transient raised alanine aminotransferase (ALT). Importantly, all three children were treated 10 with intravenous methylprednisolone and immunoglobulin with significant and sustained improvement in 11 their motor and language function, and normalisation of imaging. Immune-mediated encephalitis can 12 masquerade as subacute neuroregression. 13 M A N U S C R I P T
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Introduction 1
Type I interferonopathies are a novel group of multiple monogenic autoinflammatory and autoimmune 2 disorders presenting with early-onset systemic and organ-specific disease and characterized by genetic 3 upregulation of the antiviral type I interferon axis with heterogeneous and expanding phenotypes. To 4 date 18 different causative genes have been identified 1 . This was first described as the classical 5 phenotype of Aicardi-Goutières syndrome (AGS), a genetic leukoencephalopathy mimicking a 6 congenital infection and characterized by progressive cerebral atrophy, basal ganglia calcification and 7
lymphocytosis. 8 9
Interferons play an important role in the immune response against viral infections. The secretion of 10 these cytokines is normally induced by activation of recognition receptors of the innate immune system 11 after exposure to viral nucleic acids 1 . Abnormalities in these test results can also occur in acquired 12 conditions such as autoimmune disorders and viral infections although not typically seen in antibody-13 mediated encephalopathies 2, 3 . Until recently, it was difficult to directly measure type 1 interferon (IFN) 14 concentrations in biological samples. IFN activity is determined through IFN signature, meaning the 15 mRNA quantification of genes that are induced by IFN activity -interferon-stimulated genes (ISGs). A 16 neurological syndrome associated with raised neopterin and abnormal activation of ISGs could indicate 17 a type I interferonopathy. 2 
19
Here, we describe three children who presented with subacute motor and bulbar regression, mildly high 20 alanine aminotransferase (ALT), imaging appearances mimicking cerebral atrophy and an abnormal 21
ISGs who improved with immunotherapy suggestive of an acquired disorder. Written informed consent 22 for publication of the case description and the videos was obtained for all patients. A previously well 4-year-old girl with mild gross motor developmental delay (walked independently at 29 the age of 21 months), presented with a progressive one-year history of frequent trips and falls, 30 difficulty climbing stairs, and progressive walking difficulty needing the aid of a wheelchair for outdoors 31 (Video 3). There was also five-month history of speech regression; initially slurred incomprehensible 32 words, followed by complete loss of expressive language. She had dysphagia with choking on solids 33 and liquids and drooling. Behavioural difficulties were also reported with frequent angry outbursts andM A N U S C R I P T
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peer relationship problems. There was no history of seizures. On examination, her tone was increased 1 in the lower limbs with mixed spasticity and dystonia, right being worse than left and bilateral upgoing 2 plantars. She walked with a wide gait with both her knees hyperextended. There was drooling but no 3 cranial nerve abnormalities. Head circumference was below the 0.4th centile (no previous 4 measurements available for comparison). No hepatosplenomegaly was found. MRI brain showed mild 5 global cerebral volume loss mimicking atrophy (Figure 1-E) . At 15 months from onset she had one 6 course of three days IVMP (30mg/kg/d), followed by IVIG (2g/kg) cycles, five courses over 20 months. 7
Marked improvement in her lower limb tone, with gain in both motor and expressive language skills, 8 was observed. A repeat MRI at 13 months after treatment initiation showed reversal of previous 9 changes (Figure 1-F) . Currently, she is able to climb stairs unaided (Video 3), her speech is clear and 10 she can produce three to four word sentences. 11
12
Investigations, treatment and outcomes for all patients are summarized in Table 1 . A notable difference between patient 1 and 2 is that brain biopsy in patient 1 showed only evidence of 23 gliosis whereas biopsy in patient 2 showed clear evidence of inflammation as well as tubuloreticular 24 inclusions. This may reflect different timings of biopsies from symptom onset. On the other hand, it has 25 been previously reported that in severe inflammatory brain disorders gliosis without evidence of 26 inflammation can be the only histopathologic finding. 4 Tubuloreticular inclusions on ultrastructural 27 examination have been shown to be related to the presence of excessive interferon. 5 In addition to 28 
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We believe that patient 1's abnormally low complex IV on respiratory complex analyses is either 1 secondary or spurious, as complex IV is the most sensitive of the assays to sample handling. 2 Furthermore, no other evidence of a mitochondrial disorder was found on biochemical or genetic 3
testing. 4 5
Rasmussen encephalitis presenting with slowly progressing hemiparesis without seizures has been 6 reported. However, the bilateral presentation seen in our cases makes this diagnosis unlikely 6 . 7
A diagnosis of an antibody mediated encephalitis could be considered. The authors believe that this is 8 also unlikely as no neuronal antibody has been identified and our patients' prolonged regression is not 9 typically seen in these disorders 7 . Nevertheless, the improvement in patient 3 with mainly only IVIG 10 leaves the possibility of an unidentified antibody mediated encephalitis open. 11
12
All patients were treated with pulse IVMP and IVIG and demonstrated a quick and substantial clinical 13 improvement in their motor function, bulbar symptoms and expressive language skills in the following 14 months after treatment. All 3 patients showed relentless deterioration for several months and 15 improvement was immediately noticed within days of treatment which makes the improvements 16 observed unlikely to be part of the natural history of this disorder. The mechanisms of action of both 17 IVIG and steroids may go beyond the known immunosuppressive and immunomodulative effect and 18 may also be beneficial in patients with primary genetic conditions 8 and secondary inflammation 9 . 19
20
The milder systemic manifestation seen in the brother of patient 2 raised the possibility of an underlying 21 genetic disorder. Nevertheless, he has remained neurologically asymptomatic over the following years. 22
Several monogenic disorders mimicking acquired diseases have been described such as RANBP2 10 
23
and DARS 8 and some may respond to immunotherapy. Although the phenotype of our patients is not in 24 keeping with these known disorders we cannot rule out a yet undiscovered monogenic disorder. 25
Alternatively, as previously reported in a child with AGS with acquired NMOSD 11 , these patients could 26
have two different disorders with an underlying genetic predisposition and a second acquired insult. 27
28
We highlight the importance of evaluating children presenting with neurodegeneration of unknown 29 aetiology for CNS inflammation, assessing both innate and adaptive immunity biomarkers. 30
Immunotherapy should be considered in children presenting with this distinct phenotype of subacute 31 neuroregression, imaging appearances mimicking brain atrophy and evidence of innate immune 32 activation. This may reverse the course of the disease as exemplified by our cases. Quantitative reverse transcription-polymerase chain reaction of a panel of six interferon stimulated genes (ISGs) in whole blood measured in the three patients and the brother of patient two compared with healthy control. The relative quantification (RQ) value is equal to 2-∆∆Ct, with −∆∆Ct ± SDs (ie, the normalized fold change relative to a calibrator). Evidence of marked upregulation of type I interferon signaling was observed in all three patients and in patient's two brother. There was normalization of ISGs in patients 1 and 2 after treatment. Age at sampling: Case 1, purple bars: 3 years and 3 months (pre-treatment); 4y8m (posttreatment). Case 2, red bars: 5y3m; 5y4m; 5y5m; 5y9m (pre-treatment); 6y; 6y2m; 6y10m (posttreatment). Case 2's brother, light blue bars: 1y3m; 2y; 2y8m. Case 3, green bars: 4y7m; 5y (pre-treatment); 5y3m; 5y7m (post-treatment). Arrows under the X axis indicate treatment initiation.
Video 1 capture Video 1: A video clip of the patient in Case 1 taken in four different time points. First clip at age two years and eleven months shows dystonic posturing of both upper limbs and difficulty to grasp objects. He also had some degree of axial hypotonia with curving of the spine. Second clip at age four years with obvious dystonic posturing and movements of all four limbs with both feet on equinovarus position. Third and fourth clip at age four years and a half after treatment shows him playing with toy and tablet computer with better upper limb posturing, grasp and fine motor skills.
Video 2 capture Video 2: A video clip of the patient in Case 2 taken in two different time points. First clip at age six years and six months after treatment was started still presenting with abnormal gait pattern with increased tone and bilateral dragging her feet more marked on the left side (this was already improved compared to presentation). Second and third clips at age eight years walking up and down the stairs independently with an improved gait and riding a bicycle without any difficulties. years and six months shows a spastic/dystonic gait characterized by a wide base, hyperextended knees and feet posture into equinovarus. She was only able to walk independently for a few seconds. Third clip at age five years and eleven months shows some dystonic posturing while grasping but already with significant improvement compared to pre-treatment state. Fourth clip at age six years and four months shows her independent gait with internal rotation of both feet, more noticeable on the right side.
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Case 1 Case 2 Case 3
Brain MRI Progressive right hemispheric evolving to global symmetric volume loss. Two years after treatment: complete reversal of changes.
Generalized cerebral volume loss more marked in the right cerebral hemisphere. Three years after treatment: reversal of MRI changes.
Mild reduction in the cerebral and cerebellar white matter bulk and some delay in maturation of myelin. One year after treatment: reversal of previous volume loss.
Brain histology
Patchy gliosis with good neuronal preservation and no significant inflammation. ---
Other investigations
All patients showed: no cells, normal proteins in CSF; oligoclonal bands negative in serum and CSF; testing for antibodies associated with autoimmune encephalitis and serology screening for infections negative; normal electroencephalograms. Liver and muscle biopsies: normal, low complex IV in patient 1 (muscle), see text ---Treatment 18 months from clinical presentation: -IV Methylprednisolone (30mg/kg), 6 weekly pulses followed by IV Immunoglobulin (2g/kg), monthly.
12 months from clinical presentation: -IV Methylprednisolone (30mg/kg, 5 days) and IV Immunoglobulin (2g/kg), 4 cycles, 3 months apart.
15 months from clinical presentation: -IV Methylprednisolone (30mg/kg, 3 days) only once, followed by IV Immunoglobulin (2g/kg), 5 cycles over 20 months, ongoing. Outcome Improvement mainly in fine motor, nonverbal communication. Also, gross motor skills and speech. Able to sit unsupported and gaining new vocabulary.
Significant improvement in movement disorder and in all domains of function: gross motor, fine motor and speech.
Improvement in lower limb tone, motor and expressive language skills. Now able to climb stairs unaided, produce three to four word sentences, behavior also normalised 
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